Search

everythinglearnresearchcommunity

for

Search:↓

People discussed their experiences with anti-androgens for hair loss, mentioning side effects like chest pains with RU58841 and skepticism due to lack of safety data, while considering Fluridil as a potential addition to treatment. Some users expressed reluctance to use these chemicals.

The conversation discusses a user's three-month progress using topical finasteride once a day, 6% minoxidil at night, and weekly dermastamping at 1.25mm for hair loss. Commenters note the impressive results and discuss application methods and safety precautions for family members.

Some users of RU-58841 report cardiovascular symptoms like heart palpitations and chest tightness, which may be linked to its metabolites causing lung disease. The safety of RU-58841 is uncertain due to lack of long-term data and concerns about product purity, especially from gray market sources.

A user shared their experience with oral minoxidil and finasteride for hair loss, taking 7.5mg of minoxidil and experiencing excessive hair growth all over their body without major side effects. Some users suggested lower doses for safety, while others shared their own experiences with hair growth in different areas and side effects.

A user is considering using RU58841 to treat hair loss and asks if it can be effective for 4-5 years. Some suggest starting with a lower concentration and debate the safety of RU58841 compared to approved drugs like finasteride.

Topical finasteride remains active on the scalp for a certain period after application, and there is concern about the safety of touching the hair and transferring the medication to the fingers.

The conversation discusses switching from finasteride to dutasteride after many years to improve hair regrowth, with mixed experiences reported. One user has also used minoxidil and is hesitant to try RU58841 due to concerns about side effects and safety.

The conversation discusses improving a hair loss treatment stack without using Minoxidil. Microneedling is suggested, Alpecin is deemed ineffective, and there are concerns about the safety of Minoxidil compared to finasteride.

A user is considering microneedling to enhance absorption of a prescribed topical hair loss treatment containing Minoxidil, Dutasteride, and Latanoprost, while already taking oral Minoxidil and Dutasteride. They seek advice on the effectiveness and safety of combining these treatments, especially due to the cost and their desire to maximize results.

A recent publication suggests that the flavonoids eriocitrin and silymarin may be more effective than finasteride in binding to the enzyme responsible for hair loss. People in the conversation are skeptical about the effectiveness and safety of these flavonoids until tested on humans, and some discuss their personal experiences with other treatments.

The user experienced side effects from RU58841, including dry eyes and potential eyesight issues, and decided to stop using it. They confirmed the product's legitimacy but advised caution due to its experimental status and lack of safety data.

The conversation is about differing experiences with finasteride for hair loss, with some users reporting side effects and others not, and the debate over the drug's safety and effectiveness. Specific treatments mentioned include finasteride, dutasteride, and topical finasteride.

A 17-year-old experiencing hair loss due to hard water was advised by a dermatologist to use a treatment containing Minoxidil and vitamins. A respondent confirmed the treatment's safety but warned that discontinuing Minoxidil could worsen hair loss.

The user has been using Minoxidil and Spiro for hair loss treatment but reduced the Minoxidil dosage due to side effects, leading to increased hair loss. They are considering adding the Inkey List caffeine stimulating scalp treatment to their routine and are seeking advice on its safety and effectiveness when used with Minoxidil.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.

The post discusses the user's experience with hair loss treatment RU58841, which was tested for quality and found to be 96+% pure. The conversation includes various responses, with some users questioning the safety of the product and others expressing satisfaction with the test results.

The post discusses the use of latanoprost foam for hair growth, with the user expressing concerns about its efficiency and safety. The user is currently using topical dutasteride, which maintains their hair but doesn't promote regrowth, and is seeking a product that doesn't affect hormone levels.

The conversation discusses the risks and methods of ingesting liquid minoxidil for hair loss. Concerns include dosing accuracy, safety of ingredients, and potential side effects compared to using oral minoxidil tablets.

The conversation discusses the delay in the release of a new hair loss treatment, Pyrilutamide, and speculates on potential safety concerns as a reason for the delay. It also mentions GT20029 as another future treatment option, with a release at least five years away, and touches on the avoidance of research chemicals due to uncertainty about their authenticity.

Scientists discovered a potential baldness treatment from hairy moles, which can be injected like Botox. Users discussed the treatment's implications, including its safety and effectiveness.

The post and conversation are about the use of oral Minoxidil (Min), Finasteride (Fin), and RU58841 for hair loss treatment, with mixed opinions on their safety and effectiveness.

Dutasteride mesotherapy involves micro injections every 3 months to reduce side effects compared to regular finasteride. The discussion focuses on its effectiveness and safety for hair loss treatment.

A user discussed using KeraXL serum for hair loss, which contains Biochanin-A from Red clover extract and Acetyl Tetrapeptide-3. They sought feedback on its safety and effectiveness.

The conversation discusses the potential availability of a new hair loss treatment, GT20029, on the grey market, with users suggesting it could be within a year but advising against using grey market products due to safety concerns and complexity of the drug.

Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.

Kintor Pharma completed enrolling subjects for a Phase III trial of KX-826 for male hair loss treatment. The trial includes a 24-week treatment period and a 4-week safety follow-up, with results expected in about 6-7 months.

The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.

AnagenInc is ready to produce a hair loss treatment called GT20029 if there is enough demand. People are discussing combining it with other treatments like finasteride and minoxidil, and some are concerned about the legitimacy and safety of gray market products.

Comparing the effectiveness of RU58841, Pyrilutamide and CB-03-01 as treatments for hair loss, with people discussing different aspects such as binding affinity, time of inhibition, safety data and cost.